Phase 3 Trials Show Upadacitinib Effective for Skin Repigmentation in Nonsegmental Vitiligo

New Phase 3 data published in The Lancet from the Viti-Up-1 and Viti-Up-2 trials demonstrate that oral upadacitinib, a selective Janus kinase 1 (JAK1) inhibitor, significantly improved facial and total-body repigmentation in adults and adolescents with nonsegmental vitiligo. This is a notable development as nonsegmental vitiligo has not had an FDA-approved systemic treatment option. The safety profile observed was consistent with previous data for upadacitinib.